MannKind Corporation EVP General Counsel & Secretary David Thomson sold 123,000 shares of common stock between July 15 and July 17, 2026, at a weighted average price of $4.08 per share, totaling about $500,000. The majority of the disposition, 98,426 shares, was a non-discretionary withholding by the company to cover tax liabilities from the vesting of performance-based restricted stock units that paid out at 83% of target after MannKind's total shareholder return ranked at the 41.5th percentile of the Russell 3000 Pharmaceutical & Biotechnology Index over a three-year period ending June 30, 2026. The remaining 24,109 shares were sold under a Rule 10b5-1 trading plan established on December 2, 2025. Following the transactions, Thomson directly holds nearly 798,000 shares valued at $3.21 million based on the July 17, 2026 close. The filing comes as MannKind faces uncertainty over its Tyvaso DPI royalty stream, which generated $32.7 million in the first quarter, after United Therapeutics launched a competing inhaler called Tresmi.
MannKind CorpInsider sale of 123,000 shares, mostly for tax withholding, but also includes planned sales under 10b5-1 plan.
United Therapeutics CorporationUnited Therapeutics launched Tresmi, a competing inhaler that challenges MannKind's Tyvaso DPI.